Opinion|Videos|August 28, 2024
Advancing CML Management Towards an Ideal Patient Journey
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?
- What excites you most about the potential advancements in CML management that may be on the horizon in the next 5-10 years?
- How do you envision the CML patient experience being transformed compared to today?
Advertisement
Related to this article
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
Advertisement
Advertisement
Trending on CURE
1
What Is a Whipple Procedure? Pancreatic Cancer Surgery Explained
2
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
3
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
4
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
5